MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-13-2024
TRACON Pharmaceuticals ROCE Ratio 2011-2026 | TCON
Annual ROCE Ratio TRACON Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1146.23 | 390.07 | -241.99 | -64.71 | -354.64 | -127.94 | -74.84 | -73.2 | -59.64 | -24.8 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1146.23 | -354.64 | 51.45 |
Quarterly ROCE Ratio TRACON Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 379.55 | 290.23 | 122.49 | 364.5 | 555.02 | 795.51 | 148.88 | 112.4 | -166.09 | -485.78 | -135.08 | -150.43 | -129.3 | -72.24 | -48.05 | -236.37 | -409.35 | -623.42 | -685.1 | -727.46 | -581.5 | -395.63 | -125.96 | -117.76 | -67.19 | -59.04 | -69.79 | -89.55 | -117.51 | -108.51 | -70.23 | -90.36 | -90.73 | -71.13 | -40.77 | -35.48 | -10.06 | 1.37 | 12.2 | 12.2 | 6.91 | 4.14 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 795.51 | -727.46 | -76.3 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 4.58 | - | $ 11 B |  Australia |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.67 | - | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.32 | - | $ 148 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-631.87 | $ 22.8 | - | $ 297 M | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 26.79 | - | $ 16.8 B |  Danmark |
 |
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 102.06 | - | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
13.96 | $ 23.69 | - | $ 1.6 B | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.09 | - | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.29 | - | $ 2.96 B | USA |
 |
Jaguar Health
JAGX
|
245.65 | $ 0.24 | - | $ 560 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
4132.68 | $ 19.24 | - | $ 1.04 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.48 | - | $ 394 M | Britain |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.15 | - | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 11.85 | - | $ 1.57 B | Australia |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.91 | - | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
-39.87 | $ 0.79 | -0.65 % | $ 27.9 M | Israel |